This trial is evaluating whether Carvedilol will improve 3 primary outcomes and 6 secondary outcomes in patients with Cardiomyopathies. Measurement will happen over the course of 12 months.
This trial requires 69 total participants across 2 different treatment groups
This trial involves 2 different treatments. Carvedilol is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Cardiotoxicity in the context of chemotherapy is not uncommon as an adverse effect and is usually reversible. Some chemotherapies may be cardiotoxic and should be carefully considered when used for the treatment of breast cancer." - Anonymous Online Contributor
"Cardiotoxicity includes the toxicity of agents, drugs and other substances in the body that cause damage to cardiac system. Findings from a recent study, cardiac damage from citalopram overdose may manifest as sudden cardiac death. Cardiotoxicity may occur after the usage of the drug for a long time. Furthermore, even in those who have heart disease, there are no precautions to take." - Anonymous Online Contributor
"Some signs of cardiotoxicity are coughing blood, decreased exercise tolerance, unexplained weight loss and decreased appetite. Other signs are shortness of breath, heart murmur and arrhythmias.\n" - Anonymous Online Contributor
"Results from a recent paper, only 1 out of 9 patients with suspected cardiotoxicity had a congenital heart defect. Therefore, other factors cause cardiotoxicity in this population." - Anonymous Online Contributor
"In the United States in 1999, 2.5 million people reported cardiotoxicity in the last year, with 10% of mortality attributable to cardiotoxicity. This warrants a serious need for educational campaigns highlighting the impact of cardiotoxicity." - Anonymous Online Contributor
"Treatment of acute myeloid leukemia with TPA resulted in a significant increase in QTc and increased risk of premature ventricular complexes (PVC) or fibrillation, which may, in turn, lead to life-threatening cardiac arrest and/or death. Results from a recent paper of this study do not support the use of TPA based on the currently available data." - Anonymous Online Contributor
"Carvedilol is associated with only 0.3% of the side effects in patients in the short term. The use of carvedilol did not result in any drug-drug interaction. Long-term data on this issue are yet to be published. However, it can be safely assumed that carvedilol is often used in combination with other drugs." - Anonymous Online Contributor
"Because cardiac toxicity is thought to be a heritable trait, identification of family members who are at a higher risk for development of cardiac toxicity will allow early detection and intervention to prevent cardiotoxicity." - Anonymous Online Contributor
"The cardiac side effects (e.g. cardiovascular, peripheral artery disease) of the chemotherapeutics used for cancer treatment seem to be similar with or without the presence of an IHD. The use of a chemotherapeutic drug in IHD should be cautiously considered if heart performance is suspected to be impaired due to IHD." - Anonymous Online Contributor
"In a recent study, findings will help define the role of carvedilol in the therapeutic guidelines in order to optimize its use in terms of dosage and duration of treatment. Moreover, they may also be helpful for the medical community to better understand its safety profile and its interactions with other drugs, thus helping to guide better decisions about its management." - Anonymous Online Contributor
"In patients with left-ventricular dysfunction, carvedilol is more effective for treating diastolic dysfunction and improving LV systolic function when compared with placebo. Carvedilol's improvement in LV systolic function can be accomplished without worsening systolic function in patients with diastolic dysfunction." - Anonymous Online Contributor
"[Preliminary clinical trials of ACE inhibitors, angiotensin II receptor antagonists and beta-blockers]were conducted, but the research has yet to reach a large-scale randomized controlled trial.\n[However, in a 2008 preliminary clinical trial of the angiotensin II receptor antagonist, losartan, patients treated with losartan had a 3-year survival rate of 64.6!%, considerably greater than that of 33." - Anonymous Online Contributor